PriceTargets.com logo

Chugai Pharmaceutical - CHGCY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$16.79 As of 04/23/2024 01:00 AM ET
▲ +0.15 (0.90%)

This chart shows the closing price for CHGCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chugai Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHGCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHGCY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Chugai Pharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $16.79.

This chart shows the closing price for CHGCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Chugai Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/23/2023Sanford C. BernsteinInitiated CoverageOutperform
7/28/2022CitigroupUpgradeNeutral ➝ Buy
1/13/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy
3/12/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
12/9/2019Jefferies Financial GroupInitiated CoverageBuy
(Data available from 4/24/2019 forward)

News Sentiment Rating

1.26 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Chugai Pharmaceutical logo
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Read More

Today's Range

Now: $16.79
Low: $16.47
High: $17.21

50 Day Range

MA: $19.10
Low: $15.89
High: $21.94

52 Week Range

Now: $16.79
Low: $12.28
High: $22.61

Volume

176,502 shs

Average Volume

159,985 shs

Market Capitalization

$55.24 billion

P/E Ratio

23.99

Dividend Yield

1.12%

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Chugai Pharmaceutical?

The following sell-side analysts have issued reports on Chugai Pharmaceutical in the last year: Sanford C. Bernstein.
View the latest analyst ratings for CHGCY.

What is the current price target for Chugai Pharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Chugai Pharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Chugai Pharmaceutical in the next year.
View the latest price targets for CHGCY.

What is the current consensus analyst rating for Chugai Pharmaceutical?

Chugai Pharmaceutical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHGCY will outperform the market and that investors should add to their positions of Chugai Pharmaceutical.
View the latest ratings for CHGCY.

What other companies compete with Chugai Pharmaceutical?

Other companies that are similar to Chugai Pharmaceutical include Cencora, McKesson, Cardinal Health, Edwards Lifesciences and DexCom. Learn More about companies similar to Chugai Pharmaceutical.

How do I contact Chugai Pharmaceutical's investor relations team?

Chugai Pharmaceutical's physical mailing address is 15F, Nihombashi Mitsui Tower, Chuo Ku, Tokyo To 103-8324. The company's listed phone number is (133) 281-6611. The official website for Chugai Pharmaceutical is www.chugai-pharm.co.jp. Learn More about contacing Chugai Pharmaceutical investor relations.